DEXKETOPROFEN
Breast Neoplasm Female
Aga Khan UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Breast Neoplasm Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Peg-G-Csf Kexing Biopharm Co., Ltd. | Phase 3 | B |
Nivolumab Providence Health & Services | Phase 2 | B |
5-ala SBI ALApharma Canada, Inc. | Phase 3 | CCC |
Vesanoid Mario Negri Institute for Pharmacological Research | Phase 2 | CCC |
AK105 Liaoning Cancer Hospital & Institute | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →